Amendment: SEC Form SCHEDULE 13D/A filed by OPKO Health Inc.
$OPK
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 28)
|
OPKO HEALTH, INC. (Name of Issuer) |
Common Stock, par value $0.01 per share (Title of Class of Securities) |
68375N103 (CUSIP Number) |
Camielle Green
4400 Biscayne Blvd.,
Miami, FL, 33137
3055754100
4400 Biscayne Blvd.,
Miami, FL, 33137
3055754100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/29/2026
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP Number(s): | 68375N103 |
| 1 |
Name of reporting person
FROST PHILLIP MD ET AL | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO, WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
255,429,406.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
34.1 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
(1) The amount provided in Item 11 includes (i) 3,068,951 shares of Common Stock held individually by Dr. Frost; (ii) 30,127,177 shares of Common Stock held by the Frost Nevada Investments Trust, which is controlled by Dr. Frost as sole trustee; (iii) options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days; (iv) 216,706,448 shares of Common Stock held by the Gamma Trust, which is controlled by Dr. Frost as sole trustee; (v) 2,851,830 shares of Common Stock held by the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, and (vi) 250,000 restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock that will vest within 60 days. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock.
(2) The percentage provided in Item 13 is calculated based on (i) 746,328,225 shares outstanding as of June 29, 2026, as communicated by the Issuer to the Reporting Person; (ii) options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days; and (iii) 250,000 restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock that will vest within 60 days.
SCHEDULE 13D
|
| CUSIP Number(s): | 68375N103 |
| 1 |
Name of reporting person
Frost Gamma Investments Trust | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
FLORIDA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
216,706,448.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
29.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
(1) The percentage provided in Item 13 is calculated based on 746,328,225 shares outstanding as of June 29, 2026, as communicated by the Issuer to the Reporting Person.
SCHEDULE 13D
|
| CUSIP Number(s): | 68375N103 |
| 1 |
Name of reporting person
Frost Nevada Investments Trust | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
FLORIDA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
30,127,177.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
(1) The percentage provided in Item 13 is calculated based on 746,328,225 shares outstanding as of June 29, 2026, as communicated by the Issuer to the Reporting Person.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.01 per share | |
| (b) | Name of Issuer:
OPKO HEALTH, INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
4400 BISCAYNE BLVD., MIAMI,
FLORIDA
, 33137. | |
Item 1 Comment:
This Amendment No. 28 (the "Amendment") amends and supplements the statement on Schedule 13D filed on February 15, 2007, as amended by Amendment No. 1 to the Schedule 13D filed on April 6, 2007, as amended by Amendment No. 2 to the Schedule 13D filed on August 2, 2007, as amended by Amendment No. 3 to the Schedule 13D filed on February 14, 2008, as amended by Amendment No. 4 to Schedule 13D filed on August 21, 2008, as amended by Amendment No. 5 to the Schedule 13D filed on February 26, 2009, as amended by Amendment No. 6 to the Schedule 13D filed on March 19, 2009, as amended by Amendment No. 7 to the Schedule 13D filed on October 1, 2009, as amended by Amendment No. 8 to the Schedule 13D filed on March 28, 2011, as amended by Amendment No. 9 to the Schedule 13D filed on October 24, 2011, as amended by Amendment No. 10 to the Schedule 13D filed on October 11, 2012, as amended by Amendment No. 11 to the Schedule 13D filed on March 21, 2013, as amended by Amendment No. 12 to the Schedule 13D filed on September 16, 2013, as amended by Amendment No. 13 to the Schedule 13D filed on February 17, 2015, as amended by Amendment No. 14 to the Schedule 13D filed on December 18, 2015, as amended by Amendment No. 15 to Schedule 13D filed on September 20, 2017, as amended by Amendment No. 16 to Schedule 13D filed on November 20, 2018, as amended by Amendment No. 17 to Schedule 13D filed on March 20, 2019, as amended by Amendment No. 18 to Schedule 13D filed on March 22, 2019, as amended by Amendment No. 19 to Schedule 13D filed on November 1, 2019, as amended by Amendment No. 20 to Schedule 13D filed on August 19, 2022, as amended by Amendment No. 21 to Schedule 13D filed on February 21, 2023, as amended by Amendment No. 22 to Schedule 13D filed on January 22, 2024, as amended by Amendment No. 23 to schedule 13D filed on January 24, 2024, as amended by Amendment No. 24 to schedule 13D filed on August 29, 2024, as amended by Amendment No. 25 to schedule 13D filed on November 15, 2024, as amended by Amended No. 26 to schedule 13D filed on April 3, 2025, as amended by Amendment No. 27 to schedule 13D filed on October 1, 2025 (collectively, the "Original Schedule 13D"), by The Frost Group, LLC (the "Frost Group"), a previously reporting entity, Frost Gamma Investments Trust ("Gamma Trust"), Frost Nevada Investments Trust ("Frost Nevada"), and Phillip Frost, M.D. ("Dr. Frost"). This Amendment is filed pursuant to the Joint Filing Agreement as executed by the reporting persons listed on the cover pages to this Amendment. The Joint Filing Agreement, filed as Exhibit 1 to Amendment No. 15 to the Schedule 13D filed on September 20, 2017, is hereby incorporated by this reference. This Amendment is filed with respect to the common stock, par value $0.01 per share ("Common Stock"), of OPKO Health, Inc., a Delaware corporation (the "Issuer").
This Amendment is being filed solely as a result of a change in the Issuer's number of outstanding shares of Common Stock. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Gamma Trust directly beneficially owns 216,706,448 shares of Common Stock, which constitute approximately 29.0% of the Issuer's outstanding shares of Common Stock, based upon 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person.
Frost Nevada directly beneficially owns 30,127,177 shares of Common Stock, which constitute approximately 4.0% of the Issuer's outstanding shares of Common Stock, based upon 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person.
Dr. Frost individually owns (i) 3,068,951 shares of Common Stock, (ii) stock options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and (iii) 500,000 restricted stock units of which 250,000 units will vest within 60 days of the date hereof, and he has sole voting and dispositive power over each. The Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock.
The 255,429,406 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 34.1% of the Issuer's outstanding shares of Common Stock, based upon (i) 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person; (ii) options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof; and (iii) 250,000 restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock that will vest within 60 days of the date hereof. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock, which will not begin to vest until July, 2027. | |
| (b) | Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 216,706,448 shares of Common Stock held by Gamma Trust.
Dr. Frost is the sole trustee of Frost Nevada and holds sole voting and dispositive power with respect to 30,127,177 shares of Common Stock owned by Frost Nevada.
The Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. Dr. Frost has shared voting and dispositive power with respect to 2,851,830 shares of Common Stock owned by the Phillip and Patricia Frost Philanthropic Foundation, Inc. Dr. Frost individually owns and has sole voting and dispositive power over each of (i) 3,068,951 shares of Common Stock, (ii) stock options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and (iii) 250,000 restricted stock units that will vest within 60 days of the date hereof. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock, which will not begin to vest until July, 2027. | |
| (c) | In the last 60 days prior to the filing of this Amendment No. 28, Gamma Trust, Frost Nevada and Dr. Frost have not effected any transactions in the shares of Common Stock. | |
| (d) | Except as described herein, no other person is known by any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|